Fusion Pharmaceuticals To Acquire Phase 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
Fusion
Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage
oncology company focused on developing next-generation targeted alpha therapies
("TATs") as precision medicines, today announced the acquisition from
RadioMedix, Inc. ("RadioMedix") of the investigational new drug
application ("IND") for an ongoing Phase 2 clinical trial (the
"TATCIST" trial) evaluating 225Ac-PSMA I&T, a small molecule
targeting prostate specific membrane antigen ("PSMA") expressed on
prostate cancers. Following the closing, the alpha-emitting radiopharmaceutical
being evaluated in the TATCIST trial will be known as FPI-2265..
To read more please visit:
Source: Fusion